● TIER 3 — Information onlyGRADE BGH secretagogues & GH axis
Ipamorelin
Ghrelin-receptor agonist. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Muscle / body composition · Recovery / injury
FDA status
Not approved.
Compounding (503A/503B)
503B Category 2 (Sep 29 2023); 503A: nominated-but-withdrawn
DEA
Not controlled.
WADA (sport)
S2.2.4 GH-releasing factors: GHRH & analogues (CJC-1295, sermorelin, tesamorelin), GHS (ibutamoren, ipamorelin), GHRPs (GHRP-2/6, hexarelin)
Mechanism
Selective GHS-R1a agonist.
Human evidence · 1
no benefit over placebo. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Reference only. This page summarizes publicly available regulatory and research information about Ipamorelin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.